Her2 positive subtype and breast cancer brain metastasis: any effect of anti-Her2 targeted therapy?

被引：0
|
作者：
Kadri Altundag
机构：
[1] MKA Breast Cancer Clinic,
来源：
Journal of Neuro-Oncology | 2017年 / 135卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：639 / 639
相关论文
共 50 条
  • [41] Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
    Schoellhammer, Hans F.
    Hsu, Felicia
    Vito, Courtney
    Chu, Peiguo
    Park, Jinha
    Waisman, James
    Kim, Joseph
    BMC CANCER, 2014, 14
  • [42] Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
    Hans F Schoellhammer
    Felicia Hsu
    Courtney Vito
    Peiguo Chu
    Jinha Park
    James Waisman
    Joseph Kim
    BMC Cancer, 14
  • [43] HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
    Alison E. Smith
    Emanuela Ferraro
    Anton Safonov
    Cristina Bernado Morales
    Enrique J. Arenas Lahuerta
    Qing Li
    Amanda Kulick
    Dara Ross
    David B. Solit
    Elisa de Stanchina
    Jorge Reis-Filho
    Neal Rosen
    Joaquín Arribas
    Pedram Razavi
    Sarat Chandarlapaty
    Nature Communications, 12
  • [44] HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment
    Altundag, Kadri
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (01) : 261 - 261
  • [45] HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment
    Kadri Altundag
    Breast Cancer Research and Treatment, 2019, 175 : 261 - 261
  • [46] Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
    You, Ji Young
    Park, Kyoung Hwa
    Lee, Eun Sook
    Kwon, Youngmee
    Kim, Kyoung Tae
    Nam, Seungyoon
    Kim, Dong Hee
    Bae, Jeoung Won
    CANCER CONTROL, 2023, 30
  • [47] Targeting the mevalonate pathway in HER2-positive breast cancer to overcome resistance to anti-HER2 therapy
    Sethunath, Vidyalakshmi
    Hu, Huizhong
    De Angelis, Carmine
    Veeraraghavan, Jamunarani
    Qin, Lanfang
    Rimawi, Motthaffar F.
    Osborne, Kent C.
    Schiff, Rachel
    CANCER RESEARCH, 2018, 78 (04)
  • [48] Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
    You, Ji Young
    Park, Kyoung Hwa
    Lee, Eun Sook
    Kwon, Youngmee
    Kim, Kyoung Tae
    Nam, Seungyoon
    Kim, Dong Hee
    Bae, Jeoung Won
    CANCER CONTROL, 2022, 29
  • [49] Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution
    Giugliano, Federica
    Carnevale Schianca, Ambra
    Corti, Chiara
    Ivanova, Mariia
    Bianco, Nadia
    Dellapasqua, Silvia
    Criscitiello, Carmen
    Fusco, Nicola
    Curigliano, Giuseppe
    Munzone, Elisabetta
    CANCERS, 2023, 15 (05)
  • [50] Adjuvant therapy in breast cancer HER2 positive
    Olivito, V.
    De Simone, R.
    La Gattuta, G.
    Lucia, M.
    Dima, G.
    Talarico, R.
    Filippelli, G.
    ANNALS OF ONCOLOGY, 2006, 17 : VII146 - VII146
12345